VivoSeq
Other

Monoclonal Gammopathy

14

Pipeline Programs↗

7

Active Trials↗

7

Companies Involved↗

Monoclonal Gammopathy is an emerging landscape with 14 programs across 7 companies. The most active players are Salix, RECORDATI GROUP, Johnson & Johnson. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

6/100

Mech. Concentration

22/100

Completion Rate

50/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Salix

1 program

Phase 1R

RECORDATI GROUP

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2Regeneron logo

Regeneron

1 program

Phase 2B

BeOne Medicines

1 program

Phase 2K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

62%

Small molecule

8 of 13 classified programs — the dominant modality here.

38%ALL OTHERSMonoclonal antibody538%

Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 100% of 14 pipeline programs.

Analysis

Trial Status

13

clinical trials

Recruiting6 · 46%
Completed3 · 23%
Terminated2 · 15%
Active, not recruiting1 · 8%
Withdrawn1 · 8%

Clinical Trials

Trial Activity

13 trials

The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland
Recruiting·HHelsinki University Central Hospital·Phase 2·NCT06889948·30 enrolled
Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy
Recruiting·UUMC Utrecht·Phase 2·NCT05939037·35 enrolled
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
Recruiting·UUniversity of Rochester·Phase 2·NCT04731844·40 enrolled
Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance
Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT07209371·50 enrolled
Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
Recruiting·—·Phase 2·NCT04614558·27 enrolled
Phase 2 Dose-Ranging and Interception Study of Linvoseltamab in Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Recruiting·Regeneron logoRegeneron·Phase 2·NCT06140524·116 enrolled
Rifaximin in Patients With Monoclonal Gammopathy
Active, not recruiting·EEmory University·Phase 1·NCT03820817·50 enrolled
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
Completed·National Cancer Institute (NCI)·Phase 2·NCT00099047·23 enrolled
A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT01219010·30 enrolled
RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00259974·60 enrolled
Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance
Terminated·MMayo Clinic·Phase 2·NCT00588822·21 enrolled
Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance
Terminated·—·Phase 2·NCT00665652·8 enrolled
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma
Withdrawn·—·Phase 1·NCT03591614

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)